Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

Fehse, Frauke; Trautmann, Michael; Holst, Jens J; Halseth, Amy E; Nanayakkara, Nuwan; Nielsen, Loretta L; Fineman, Mark S; Kim, Dennis D; Nauck, Michael A

Fehse, Frauke; Trautmann, Michael; Holst, Jens J; Halseth, Amy E; Nanayakkara, Nuwan; Nielsen, Loretta L; Fineman, Mark S; Kim, Dennis D; Nauck, Michael A.

Affiliation

Fehse F; Diabeteszentrum Bad Lauterberg, Kirchberg 21, D-37431 Bad Lauterberg im Harz, Germany.

J Clin Endocrinol Metab ; 90(11): 5991-7, 2005 Nov.

Article in En | MEDLINE | ID: mdl-16144950

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Glucose/pharmacology; Insulin/metabolism; Peptides/therapeutic use; Venoms/therapeutic use; Adult; Diabetes Mellitus, Type 2/metabolism; Exenatide; Female; Glucagon-Like Peptide 1/therapeutic use; Humans; Insulin Secretion; Male; Middle Aged

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Venoms / Diabetes Mellitus, Type 2 / Glucose / Insulin Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Clin Endocrinol Metab Year: 2005 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links